Foresee Pharmaceuticals Co Ltd Total Liabilities
Foresee Pharmaceuticals Co Ltd total liabilities. Based on the latest financial reports, Foresee Pharmaceuticals Co Ltd (6576) has total liabilities worth NT$593.99 Million TWD (≈ $18.71 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Foresee Pharmaceuticals Co Ltd (6576) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Foresee Pharmaceuticals Co Ltd (2017–2024)
Total liabilities of Foresee Pharmaceuticals Co Ltd from 2017 to 2024. This chart illustrates how Foresee Pharmaceuticals Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Foresee Pharmaceuticals Co Ltd Competitors by Total Liabilities
The table below lists competitors of Foresee Pharmaceuticals Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanxi Yongdong Chemistry Industry Co Ltd
SHE:002753
|
China | CN¥1.03 Billion |
|
Jinsanjiang (Zhaoqing) Silicon Material Company Limited
SHE:301059
|
China | CN¥420.92 Million |
|
Jiangsu Yida Chemical Co Ltd Class A
SHE:300721
|
China | CN¥1.48 Billion |
|
Ophir High Conviction Fund
AU:OPH
|
Australia | AU$28.68 Million |
|
Equinox India Developments Ltd
NSE:IBREALEST
|
India | Rs115.74 Billion |
|
Agro Tech Foods Limited
NSE:ATFL
|
India | Rs1.33 Billion |
|
Aurora Corp
TW:2373
|
Taiwan | NT$9.26 Billion |
|
Tus-Sound Environmental Resources Co Ltd
SHE:000826
|
China | CN¥17.71 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Foresee Pharmaceuticals Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Foresee Pharmaceuticals Co Ltd asset portfolio.
Liquidity & Leverage Metrics
Foresee Pharmaceuticals Co Ltd Total Liabilities Ratios Explained
Foresee Pharmaceuticals Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Foresee Pharmaceuticals Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Foresee Pharmaceuticals Co Ltd (2017–2024)
The table below shows the annual total liabilities of Foresee Pharmaceuticals Co Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$560.15 Million ≈ $17.65 Million |
-9.20% |
| 2023-12-31 | NT$616.93 Million ≈ $19.44 Million |
+56.81% |
| 2022-12-31 | NT$393.43 Million ≈ $12.40 Million |
+22.47% |
| 2021-12-31 | NT$321.26 Million ≈ $10.12 Million |
+18.81% |
| 2020-12-31 | NT$270.40 Million ≈ $8.52 Million |
+138.45% |
| 2019-12-31 | NT$113.40 Million ≈ $3.57 Million |
-10.00% |
| 2018-12-31 | NT$125.99 Million ≈ $3.97 Million |
+26.71% |
| 2017-12-31 | NT$99.44 Million ≈ $3.13 Million |
-- |
About Foresee Pharmaceuticals Co Ltd
Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release … Read more